This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (52)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Multiple Sclerosis/ Demyelinating Disease  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Rate of Brain Atrophy Is Independent of the Disease Subtype

Nynke F. Kalkers, MD, PhD; Najim Ameziane, MSci; Joost C. J. Bot, MD; Arjan Minneboo, MD; Chris H. Polman, MD, PhD; Frederik Barkhof, MD, PhD

Arch Neurol. 2002;59:1572-1576.

Background  In multiple sclerosis (MS), brain atrophy depicted by magnetic resonance imaging reflects overall tissue loss, including axonal loss.

Objective  To determine the course of atrophy by studying the rate of development of brain atrophy in patients who have different subtypes of MS.

Methods  Eighty-three patients with MS (42 with relapsing-remitting, 21 with secondary progressive, and 20 with primary progressive) were studied longitudinally, with an interval of 2 to 4 years. Magnetic resonance imaging included T1- and T2-weighted images to obtain 2 brain volume measurements: (1) the parenchymal fraction as a marker of global brain atrophy and (2) the ventricular fraction as a marker of central atrophy. The annualized rate of global and central brain atrophy was compared between those with different subtypes of MS and related to clinical characteristics, including sex, age, disease duration, and disability.

Results  There was a significant decrease of the parenchymal fraction (-0.7% per year; SEM, 0.11% per year) and a significant increase of ventricular fraction (3.7% per year; SEM, 0.54% per year) in the total group. Significant tissue loss was also seen in all 3 subtypes of MS; the decrease in parenchymal fraction was not different between subtypes, whereas the increase in ventricular fraction tended to be larger in patients with secondary progressive MS compared with patients with primary progressive MS. Marginal associations were found between clinical determinants and the rate of brain atrophy. Annualized increase in the ventricular fraction was correlated with age (r = -0.26) and duration of symptoms (r = -0.22): younger patients (mainly patients with relapsing-remitting MS who have a limited disability) displayed a larger increase in ventricular fraction compared with older patients.

Conclusions  The rate of development of brain atrophy is largely independent of the course of the disease and other clinical characteristics. The relentless loss of tissue occurring in MS is not restricted to later (progressive) phases of the disease, thereby stressing the need for early neuroprotective treatment in MS.

From the Departments of Neurology (Drs Kalkers and Polman) and Radiology (Mr Ameziane and Drs Bot, Minneboo, and Barkhof), Vrije Universiteit Medical Center, Amsterdam, the Netherlands.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Association between MRI parameters and the MS severity scale: a 12 year follow-up study
Minneboo et al.
Mult Scler 2009;15:632-637.
ABSTRACT  

Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics?
Korteweg et al.
Mult Scler 2009;15:465-471.
ABSTRACT  

Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis
Altmann et al.
Neurology 2009;72:595-601.
ABSTRACT | FULL TEXT  

Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study
Tedeschi et al.
Mult Scler 2009;15:204-211.
ABSTRACT  

Progression of non-age-related callosal brain atrophy in multiple sclerosis: a 9-year longitudinal MRI study representing four decades of disease development
Juha et al.
J. Neurol. Neurosurg. Psychiatry 2007;78:375-380.
ABSTRACT | FULL TEXT  

Determinants of Cerebral Atrophy Rate at the Time of Diagnosis of Multiple Sclerosis
Jasperse et al.
Arch Neurol 2007;64:190-194.
ABSTRACT | FULL TEXT  

Onset and underpinnings of white matter atrophy at the very early stage of multiple sclerosis - a two-year longitudinal MRI/MRSI study of corpus callosum
Audoin et al.
Mult Scler 2007;13:41-51.
ABSTRACT  

Multiple Sclerosis: The Role of MR Imaging
Ge
Am. J. Neuroradiol. 2006;27:1165-1176.
ABSTRACT | FULL TEXT  

Granzyme B mediates neurotoxicity through a G-protein-coupled receptor
Wang et al.
FASEB J. 2006;20:1209-1211.
ABSTRACT | FULL TEXT  

Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis.
Frohman et al.
Arch Neurol 2006;63:614-619.
FULL TEXT  

Brain atrophy and lesion load in a large population of patients with multiple sclerosis
Tedeschi et al.
Neurology 2005;65:280-285.
ABSTRACT | FULL TEXT  

Multiple sclerosis: looking beyond autoimmunity
Chaudhuri and Behan
JRSM 2005;98:303-306.
FULL TEXT  

Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study
Sastre-Garriga et al.
Brain 2005;128:1454-1460.
ABSTRACT | FULL TEXT  

Regional Brain Atrophy Evolves Differently in Patients with Multiple Sclerosis According to Clinical Phenotype
Pagani et al.
Am. J. Neuroradiol. 2005;26:341-346.
ABSTRACT | FULL TEXT  

Rate of brain atrophy in relapsing MS decreases during treatment with IFN{beta}-1a
Hardmeier et al.
Neurology 2005;64:236-240.
ABSTRACT | FULL TEXT  

Pathological study of spinal cord atrophy in multiple sclerosis suggests limited role of local lesions
Evangelou et al.
Brain 2005;128:29-34.
ABSTRACT | FULL TEXT  

Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study
Rovaris et al.
Brain 2003;126:2323-2332.
ABSTRACT | FULL TEXT  

Neurotoxicity, Neuroplasticity, and Magnetic Resonance Imaging Morphometry--Reply
Weinberger and McClure
Arch Gen Psychiatry 2003;60:848-849.
FULL TEXT  

Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy
Eikelenboom et al.
Neurology 2003;60:219-223.
ABSTRACT | FULL TEXT